EVALUATION OF THE EXPRESSION OF TLE3 IN SEROUS OVARIAN CANCER

Abstract

Indications for treatment of ovarian cancer with taxane derivatives requires individualization, and this is necessary to have a reliable marker allowing to determine the rationality of the using of cytostatics. One of the progressive trends in this issue may be related to the immunohistochemical identification in removed tumors of transducing-like protein TLE3, which is a transcriptional repressor that is involved in the differentiation of epithelial cells and carcinogenesis. In the present study retrospectively analyzed 100 patients and prospectively 73 patients with serous ovarian cancer treated in MCCOC from 2007 to2014. In the first stage of treatment all patients underwent debulking surgery followed by adjuvant chemotherapy with platinum and taxanes or cyclophosphamide. Providing of immunohistochemical investigation of removed tumor tissue was carried out with a standard peroxidase-antiperoxidase method. Statistically significant influence of expression of TLE3 on disease-free survival (log-rank = 0.023). Five-year disease-free survival in the group with positive expression of TLE3 was 1.2 times higher than in the group with negative expression of TLE3 (0.490; 95% confidence interval [0.287, 0.837] and 0.261; 95% confidence interval [0.179, 0.380], respectively). An objective response in patients with TLE3-positive tumors was obtained in 93.8%. There were no benefits of taxanes using compared with cyclophosphamide in group of patients with negative expression TLE3. Thus, it is advisable to evaluate the expression of TLE3 to identify groups of patients that are sensitive to chemotherapy with taxanes.